Access National Corp. (Nasdaq:ANCX) announced that it has launched a subsidiary Registered Investment Advisory firm, Access Capital Management, LLC (NYSE:ACM), to service its affluent business client base. ACM specializes in servicing high net worth individual, corporate and not-for-profit clients, with an approach that is consistent with Access National’s high-level, “community focused” standards.
Access National Corporation operates as the bank holding company for Access National Bank that provides commercial credit, deposit, and mortgage services to middle market businesses and associated professionals primarily in the greater Washington, D.C. Metropolitan area.
ENZO Opperational Highlights:
- Enzo Life Sciences, benefiting from increased emphasis on higher margin products, realized a greater than 100% gain in operating income.
- Enzo Clinical Labs increased revenues 6%, while reducing the operating loss 62%.
- Company-wide, gross margin increased $2.0 million or 17%.
- Operating expenses decreased 7%, or to 57% of revenues, from 63%.
- EBITDA, a non-GAAP measure, was $23,000, an improvement of $2.9 million from the prior quarter.
- Net loss for the quarter was reduced 70%.
Enzo Therapeutics Strategy
Enzo intends to exploit its broadly applicable and innovative technology platforms to develop products for treating a variety of diseases.
The broad diagnostic and therapeutic potential offered by Enzo's core technology platforms extend to applications well beyond those currently under development in-house.
For additional therapeutic applications that will not be developed in-house, Enzo seeks collaborations or partnerships with other companies that can provide a synergistic enhancement of drug development.
What is Enzo Clinical Labs?
Enzo Clinical Labs is a full service clinical reference laboratory. They are one of the leading regional labs in the country, as we combine the extensive testing capabilities of a large laboratory with the convenience and personalized service of a local one.
Enzo was one of the area’s first laboratories to be awarded the prestigious College of American Pathologist (CAP) accreditation. This award indicates that Enzo has passed an extremely rigorous series of inspections far more sophisticated than those mandated by licensing authorities.
Enzo Clinical Labs is much more than a highly respected clinical laboratory. Our lab is utilized extensively to demonstrate the benefits of gene-based products developed at Enzo Life Sciences. It also plays an important role in the development of and performance of tests used to support the on going trials of Enzo Therapeutics.
About Enzo Biochem
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including esoteric tests, to the medical community. Since our founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field.
Enzo Life Sciences develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research, among others. Its catalog of over 30,000 products serves the molecular biology, drug discovery and pathology research markets worldwide. Enzo Clinical Labs provides laboratory services for a growing roster of physicians in the New York Metropolitan area, Eastern Pennsylvania and New Jersey.
Gladstone Investment Corporation (Nasdaq:GAIN) announced that it plans to report earnings after the stock market closes on Monday, January 31, 2011 for the third quarter ended December 31, 2010. The Company will hold a conference call Tuesday, February 1, 2011 at 8:30 a.m. EST to discuss its earnings results.
Gladstone Investment Corporation specializes in buyouts and recapitalizations. It seeks to make debt and equity investments in small and mid-sized private businesses. The fund invests in junior subordinated loans, mezzanine debt, preferred stock, and warrants to purchase common stock of companies based in the the United States.
Power3 Medical Hits a Grand Slam at ICAD With Four Alzheimer’s Poster Presentations
Power3 Medical Products, Inc. (OTCBB:PWRM) announced that it delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3’s diagnostic test, and focused on Power3’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.
“In preparation for commercialization, our objective at this meeting was to show how Power3’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” said Dr. Ira L. Goldknopf, Power3’s President and Chief Scientific Officer.
“It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”
Alzheimer’s disease is among the most well known form of dementia, a broad term when it comes to forgetfulness and other intellectual abilities critical enough to obstruct everyday life. Alzheimer’s diseases is the reason for 50 to seventy per cent of dementia cases.
Alzheimer’s disease isn’t an ordinary part of getting older, even though greatest known risk factor is increasing age, along with the largest part of people today with Alzheimer’s tend to be 65 and older. But Alzheimer’s is not just a sickness of old age. Up to 5 % of people with the sickness currently have early-onset Alzheimer’s (also referred to as younger-onset), which frequently appears when ever someone is within his or her 40s or 50s.
Alzheimer’s gets worse over time. Alzheimer’s disease is a developing condition, at which symptoms slowly intensify over a period of time. Continuing, memory loss is mild, however with late-stage Alzheimer’s disease, people lose the ability to hold on a dialogue as well as react to their surroundings. Alzheimer’s is the 6th main source of death in the united states. People with Alzheimer’s are living an average of eight years following an individual’s symptoms developing into being recognizable to many others, but yet survival may range from three to 20 years, based upon years of age and various medical ailments.
About the Company
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.
Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials.
These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
PWRM expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s disease (NuroPro-AD), Parkinson’s disease (NuroPro-PD) and breast cancer in 2011, followed by filings with the FDA.
ISTA Pharmaceuticals Inc. (Nasdaq:ISTA) announced that during its previously announced guidance call, that it expects to achieve its 2010 net revenues guidance of $147 million to $167 million with anticipated, unaudited net revenues in the mid-$150 million range. The company also said it expects to exceed $1 million in unaudited net income in 2010, before any warrant expense.
ISTA Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets remedies for diseases and conditions of the eye in the United States. It provides products to treat diseases of the eye and allergies; and therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies.
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at http://crwepicks.com/disclaimer ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.
Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).